(Q51547763)

English

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. (English)

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

phase III clinical trial

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anthony M. Mills

5

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Adriano Lazzarin

object named as

Adriano Lazzarin

4

0 references

Beatriz Grinsztejn

3

object named as

Beatriz Grinsztejn

1 reference

Europe PubMed Central

6 April 2018

6

object named as

Michael Saag

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Jean-Michel Molina

1

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Sharon Walmsley

object named as

Sharon Walmsley

8

1 reference

ORCID Public Data File 2021

12

object named as

Katia Boven

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Simon Vanveggel

11

object named as

Simon Vanveggel

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

2

object named as

Pedro Cahn

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

author name string

Khuanchai Supparatpinyo

7

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Herta Crauwels

9

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Laurence T Rimsky

10

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

ECHO study group

13

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

language of work or name

0 references

publication date

1 July 2011

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

378

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

9787

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

238-246

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960936-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)60936-7

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/21763936

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51547763&oldid=2120319127"